These findings highlight tirzepatides multifaceted cardiometabolic benefits, suggesting that it may be a transformative therapy for managing both obesity and HFpEF by targeting excess adiposity, systemic inflammation, and cardiovascular risk (91)
For broader literature on potential harms in related contexts see this review at PMC
Healing Support: Enhanced blood flow supports faster recovery and reduces pain
For example, Mounjaro (tirzepatide)by Eli Lilly, though structurally a dual GIP/GLP-1 agonist, is classified within the GLP-1 class in major market reports, and reached $5.16 billion in sales in its first full year of launch
Alzghoul l, Abdelhamid s, Yanis a et al (2019) The association between levels of inflammatory markers in autistic children compared to their unaffected siblings and unrelated healthy controls